[1. Pivonello, R., De Martino, M. C., De Leo, M., Lombardi, G., & Colao, A. (2008). Cushing’s Syndrome. Endocrinol Metab Clin North Am. 37(1), 135-149, ix. doi: 10.1016/j. ecl.2007.10.010]Search in Google Scholar
[2. Newell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006). Cushing’s syndrome. Lancet. 367(9522), 1605-1617. doi: 10.1016/ s0140-6736(06)68699-6]Search in Google Scholar
[3. Poullot, A-G & Chevalier, N. (2013).New options in the treatment of Cushing’s disease: a focus on pasireotide. Research and Reports in Endocrine Disorders. 3,31-38.]Search in Google Scholar
[4. Rockall, A. G., Sohaib, S. A., Evans, D., Kaltsas, G., Isidori, A. M., Monson, J. P., Besser, G.M., Grossman, A.B. & Reznek, R. H. (2003). Hepatic steatosis in Cushing’s syndrome: a radiological assessment using computed tomography. Eur J Endocrinol. 149(6), 543-548.10.1530/eje.0.149054314640995]Search in Google Scholar
[5. Biller, B. M., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M.,Colao, A.,Hermus, A. R.,Hofland, L.J., Klibanski, A., Lacroix, A., Lindsay, J.R., Newell-Price, J., Nieman, L.K., Petersenn, S., Sonino, N., Stalla, G.K., Swearingen, B., Vance, M..L, Wass, J. & A H Boscaro, M. (2008). Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 93(7), 2454-2462. doi: 10.1210/jc.2007-273410.1210/jc.2007-2734321427618413427]Search in Google Scholar
[6. Greenman Y. (2010). Management of dyslipidemia in Cushing’s syndrome. Neuroendocrinology. 92,91-95.10.1159/00031429420829626]Search in Google Scholar
[7. Falck-Ytter, Y., Younossi, Z.M., Marchesini, G. & McCullough, A.J. (2001) Clinical features and natural history of nonalcoholic steatosis syndromes. Seminars in Liver Disease. 21,17-26.10.1055/s-2001-1292611296693]Search in Google Scholar
[8. Lacroix, A. & Pivonello, R. (2012). Medical treatment of Cushing’s disease with pasireotide. European Endocrinology. 99-104. ]Search in Google Scholar